Home / Themes / Therapeutics '26: Psychedelic Drugs

Therapeutics '26: Psychedelic Drugs (open on stockthemes)

Last updated

Theme thesis · 5/5 sections · Tickers 0 with notes · 12 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

The Biotech '26: Psychedelic Drugs theme invests in companies developing psychedelic and neuroplastogen compounds for mental health. Accelerated by favorable re

Thesis

The Biotech '26: Psychedelic Drugs theme invests in companies developing psychedelic and neuroplastogen compounds for mental health. Accelerated by favorable regulatory shifts, positive late-stage clinical data, and increasing Big Pharma interest, the sector anticipates significant market growth and potential FDA approvals for conditions like depression and PTSD, alongside the emergence of more accessible non-hallucinogenic therapies.

Bull case

  • The U.S. FDA, following an April 2026 executive order, has fast-tracked psychedelic drug research, issued finalized guidance for clinical investigations, and granted national priority vouchers to accelerate development. This regulatory momentum is leading to companies like Compass Pathways and Definium Therapeutics nearing FDA submission and potential approval for their lead candidates by late 2026 or early 2027.

  • The psychedelic therapy market is projected for substantial growth, with estimates reaching over $12 billion by 2034-2035, driven by ongoing clinical advancements and shifting mental health treatment paradigms. This growth is further validated by significant Big Pharma interest, exemplified by Eli Lilly's planned acquisition of AtaiBeckley for an estimated US$3.8 billion, signaling increasing institutional confidence and investment in the sector.

  • A growing focus on non-hallucinogenic neuroplastogens offers a pathway to broader market acceptance and scalability. These compounds aim to deliver therapeutic benefits without inducing hallucinations, potentially enabling broader outpatient use, reducing stigma, and streamlining clinical development by mitigating challenges associated with psychedelic experiences. This expands the addressable market beyond traditional psychedelic-assisted therapy.

Bear case

  • Despite accelerated pathways, psychedelic drug development faces persistent regulatory and clinical challenges. The FDA emphasizes that these programs must meet the same rigorous evidentiary standards as other drugs, while accounting for unique issues such as difficulties in blinding trials, managing expectancy bias, and assessing abuse potential. The need for long-term follow-up and careful safety planning adds complexity and cost to development.

  • The high cost and logistical complexity of psychedelic-assisted therapy, which often requires extensive supervised administration and specialized infrastructure, could limit patient access and hinder widespread insurance coverage. This may slow market penetration compared to more traditional, less resource-intensive pharmaceutical treatments.

  • Psychedelic drugs carry inherent safety concerns, including risks of acute psychological reactions (e.g., 'bad trips'), persistent mental health effects like psychosis or hallucinogen persisting perception disorder (HPPD), and specific toxicological risks (e.g., cardiac issues with ibogaine, urinary tract damage with ketamine). While clinical trials aim to mitigate these, broader commercialization could face challenges from public perception, potential misuse, and the need to balance therapeutic benefits with known risks.

Overview

Hiring Trend Watchpoints

High-performing sponsors approaching NDA filings and pivotal readouts (e.g., Compass Pathways, Definium Therapeutics, Helus Pharma) show clear workforce shifts from early discovery pharmacology toward late-stage regulatory affairs, CMC (chemistry, manufacturing, and controls), health economics and outcomes research (HEOR), and medical affairs. Execution confirmation is evidenced by postings for commercial market access directors, REMS (Risk Evaluation and Mitigation Strategies) operations managers, and field liaison networks engaging psychiatric clinics. Picks-and-shovels and clinic infrastructure operators show recruitment in GMP quality control, DEA Schedule I compliance officers, and clinical therapist trainers. Conversely, net job freezes, executive attrition in clinical development, or abrupt contractions in trial site support personnel signal operational friction, clinical hold risks, or cash runway distress.

Forum Watchlist

  • Reddit — r/PsychedelicStudiesHigh

    Peer-reviewed trial data, functional unblinding discussions, expectancy bias analyses, and academic clinical protocol critiques

  • Reddit — r/shroomstocksHigh

    Retail sentiment, corporate updates, clinical milestone expectations, financing dilution notices, and patent filings

  • Reddit — r/biotechMedium

    Industry insider perspectives on FDA advisory committee outcomes, clinical rater blinding feasibility, and Big Pharma licensing interest

  • Reddit — r/TherapeuticPsychedelicsMedium

    Real-world patient experience, clinical trial accessibility, session protocol burdens, and post-session durability observations

  • Discord — Psychedelic Medicine Coalition / Investor HubsLow

    State-level policy shifts, DEA rescheduling commentary, and clinical infrastructure buildout bottlenecks

Industry Publications

  • Psychedelic Alpha (psychedelicalpha.com) — Leading specialized intelligence platform tracking clinical pipelines, regulatory filings, intellectual property litigation, and FDA guidance compliance.
  • Fierce Biotech (fiercebiotech.com) — Premier biopharma news outlet providing timely reporting on pivotal psychiatric trial readouts, FDA AdCom hearings, and C-suite moves.
  • Lucid News (lucid.news) — Dedicated coverage of business, clinical research, legislative policy, and cultural shifts shaping the psychedelic medicine ecosystem.
  • BioSpace (biospace.com) — Key life sciences portal tracking biopharma clinical milestones, financing rounds, regulatory submissions, and talent recruitment trends.
  • Endpoints News (endpts.com) — In-depth pharmaceutical journalism covering drug development catalysts, FDA reviews, CMS reimbursement precedents, and CNS dealmaking.

Second Order Trends

1. Compression of Treatment Duration: Heavy R&D prioritization of short-acting tryptamines (e.g., inhaled 5-MeO-DMT) and deuterated molecules (e.g., HLP003) engineered to drastically curtail in-clinic monitoring time to under two hours, significantly lowering overhead costs. 2. Rise of Non-Hallucinogenic Neuroplastogens: Accelerated development of novel compounds (e.g., EB-003) designed to trigger 5-HT2A-mediated dendritic plasticity and synaptic rewiring without dissociative hallucinatory states, unlocking potential unmonitored outpatient dispensing. 3. Turnkey REMS & Interventional Psychiatry Infrastructure: Commercialization planning heavily leverages existing Spravato-certified interventional clinic footprints, shifting commercial focus toward clinic-level logistics, DEA storage compliance, and third-party payer CPT coding. 4. Strategic Big Pharma Engagement: Following proof-of-concept Phase 3 data in depression and anxiety, major CNS pharmaceutical corporations are increasing licensing, option deals, and acquisitions to replenish late-stage neuropsychiatry pipelines.

Search Keywords Brand Product

  • COMP360
  • DT120
  • DT120 ODT
  • HLP003
  • HLP004
  • GH001
  • EB-003
  • PEX010
  • LaNeo MDMA
  • CMND-100
  • psychedelic medicine
  • psilocybin therapy
  • LSD clinical trial
  • psychedelic biotech
  • neuroplastogens
  • MDMA-assisted therapy
  • treatment-resistant depression psilocybin
  • serotonergic agonist trial

Search Keywords Policy Regulatory

  • FDA psychedelic guidance
  • DEA Schedule I rescheduling
  • Breakthrough Therapy designation
  • REMS certification
  • expanded access psychedelic
  • psychedelic clinical investigation guidance

Search Keywords Event Phrases

  • FDA Advisory Committee psychedelic
  • COMP360 NDA submission
  • DT120 Phase 3 readout
  • HLP003 Phase 3 topline
  • Emerge Phase 3 trial
  • Voyage trial GAD
  • Part 15 FDA hearing psychedelics

Google Trend Product Category Intent

• COMP360 psilocybin • DT120 LSD • psilocybin clinical trial • MDMA clinical trial • neuroplastogen drug

Google Trend Consumer Intent

• psychedelic therapy near me • psilocybin for depression • MDMA treatment for PTSD • legal psychedelic therapy clinics • ketamine vs psilocybin therapy

Google Trend Macro Policy Terms

• FDA psychedelic approval • psilocybin legal status • DEA reschedule psychedelics • psychedelic medicine legalization

Economic Data Watch

1. FRED — National Health Expenditure Accounts

Matchedfred · access=api · map_only

Metric/field HLTHSCEXPHCSA

Cadence monthly

Why it matters Growth in overall healthcare spending suggests a larger addressable market and increased investment capacity for novel therapies like psychedelics, signaling a bullish trend for the theme.

Signal to watch Increasing trend

Confidence: high

2. FRED — Federal Funds Data

Matchedfred · access=api · map_only

Metric/field DFF

Cadence monthly

Why it matters Interest rates impact the cost of capital for biotech companies, influencing R&D funding and expansion plans. Lower rates are generally bullish for growth-oriented sectors.

Signal to watch Decreasing or stable low rates

Confidence: high

3. PitchBook / NVCA — Venture Capital Investment Data

Matched (medium)cand_pitchbook_nvca_fa37cb27 · candidate

Metric/field Total VC Funding to Biotechnology Sector

Cadence quarterly

Why it matters Directly tracks the flow of investment into the broader biotechnology sector, indicating investor confidence and available capital for psychedelic drug development.

Signal to watch Increasing funding amounts

Confidence: medium

4. FRED — Producer Price Index by Industry

Matchedfred · access=api · map_only

Metric/field PCU3254132541

Cadence monthly

Why it matters Tracks the input costs for pharmaceutical manufacturing, which can impact the profitability and pricing strategies of psychedelic drug developers and suppliers.

Signal to watch Stable or decreasing input costs

Confidence: high

5. FRED — Employment for Manufacturing: Pharmaceutical and Medicine Manufacturing

Matchedfred · access=api · map_only

Metric/field IPUEN3254W010000000

Cadence monthly

Why it matters Growth in employment within the pharmaceutical manufacturing sector indicates overall industry expansion and capacity, supporting the theme's growth potential.

Signal to watch Increasing employment numbers

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Database

Matched (medium)cand_clinicaltrials_gov_36d0f449 · candidate

Metric/field Number of active studies for psilocybin, MDMA, LSD, DMT, ibogaine for mental health indications (e.g., depression, PTSD, AUD)

Cadence quarterly

Why it matters Directly tracks the progress and volume of research and development in psychedelic medicine, signaling innovation and future potential for drug approvals.

Signal to watch Increasing number of active studies and patient enrollment rates

Confidence: high

2. FDA.gov — FDA Guidance Documents and Approvals

Matched (medium)cand_fda_gov_1e47d75c · candidate

Metric/field New guidance documents or approvals related to psychedelic drugs or neuroplastogens

Cadence event_driven

Why it matters FDA actions directly influence the regulatory pathway and commercial viability of psychedelic drugs, with positive guidance or approvals de-risking the sector.

Signal to watch Issuance of favorable guidance, fast-track designations, or drug approvals

Confidence: high

3. USPTO PatentsView — Patent Grants and Applications

Matched (medium)cand_uspto_patentsview_75814015 · candidate

Metric/field Number of new patent grants/applications by theme constituents or for psychedelic/neuroplastogen compounds

Cadence monthly

Why it matters Patent activity indicates innovation, competitive positioning, and the expansion of intellectual property within the psychedelic biotech space.

Signal to watch Increasing patent filings and grants

Confidence: medium

4. Google Trends — Search Interest Data

Not in registry

Metric/field Search interest for 'psychedelic therapy' and constituent product terms (e.g., 'COMP360 psilocybin', 'DT120 LSD')

Cadence weekly

Why it matters Reflects public and patient interest in psychedelic treatments, indicating growing awareness and potential demand for approved therapies.

Signal to watch Increasing search interest over time

Confidence: high

5. Reddit — Subreddit Activity Data

Matched (medium)cand_reddit_subreddit_ea54cd78 · candidate

Metric/field Post volume and sentiment in r/PsychedelicStudies and r/TherapeuticPsychedelics

Cadence daily

Why it matters Provides insights into scientific discussion, patient experiences, and community sentiment surrounding psychedelic research and therapy.

Signal to watch Increasing positive discussion volume, scientific engagement, and real-world adherence insights

Confidence: medium

Paid Alt Data Watch

1. Clarivate Life Sciences & Healthcare (e.g., Cortellis Clinical Trials Intelligence) — Clinical Trial Data

Matchedclarivate_life_sciences_drug_intelligence · access=file · map_only

Metric/field Phase progression, patient enrollment rates, and key data readouts for lead psychedelic drug candidates (e.g., COMP360, DT120, HLP003)

Cadence weekly / event_driven

Why it matters Offers granular, real-time tracking of clinical trial progress, which is critical for assessing the likelihood and timing of regulatory approvals and commercialization.

Signal to watch Positive phase advancements, strong enrollment, and favorable data readouts

Confidence: high

2. IQVIA — Prescription Data (Xponent, NPA)

Matchediqvia_prescription_rx_data · access=file · map_only

Metric/field Prescription volume and market share for newly approved psychedelic drugs or related mental health treatments

Cadence weekly / monthly

Why it matters Provides early indicators of market adoption and commercial success for approved psychedelic therapies, as well as trends in related mental health prescriptions.

Signal to watch Increasing prescription volumes and market share for theme-relevant drugs

Confidence: high

3. LinkUp / Burning Glass / data aggregators — Job Postings Data

Matchedlinkup_job_postings · access=file · map_only

Metric/field Number of job postings for 'Regulatory Affairs', 'Clinical Trial Manager', 'Medical Affairs' roles within biotech companies, specifically those linked to psychedelic or neuroplastogen development

Cadence weekly

Why it matters Hiring trends indicate strategic shifts and operational scaling. A rise in regulatory and medical affairs roles suggests companies are nearing commercialization.

Signal to watch Increasing postings for late-stage development and commercialization roles

Confidence: high

4. Apptopia — Mobile App Performance Data

Matched (medium)apptopia_app_usage_engagement · access=file · map_only

Metric/field Download and usage trends for mental health/therapy apps, especially those associated with theme members like Numinus Wellness (if applicable)

Cadence daily / weekly

Why it matters For companies focused on treatment infrastructure or digital health components, app data provides insights into patient engagement, platform adoption, and scalability.

Signal to watch Increasing downloads, active users, and engagement metrics

Confidence: high

5. GlobalData Healthcare — Market Research Reports / Forecasts

Matchedglobaldata_healthcare_healthcare_forecasts_market_sizing · access=file · map_only

Metric/field Updated market size projections and growth forecasts for the 'Psychedelic Drugs Market' or 'Psychedelic Therapy Market'

Cadence annually / event_driven

Why it matters Provides high-level validation of the theme's long-term commercial potential and helps benchmark industry growth expectations against actual performance.

Signal to watch Upward revisions in market size projections and sustained high growth rates

Confidence: high

Prediction Market Watch

1. Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)

Kalshi · Confidence: high

Matched (medium)pm_kalshi_ddr5_ye2027_above_95 · access=api

Market https://kalshi.com/markets/kxfdaapprovalpsychedelic

Why it matters This market directly reflects the overall regulatory progress and acceptance of psychedelic drugs by the FDA, which is a fundamental driver for the entire theme. A positive outcome would validate the therapeutic potential of psychedelics, potentially opening doors for broader insurance coverage and de-risking the regulatory pathway for all theme constituents.

Series key pm_fda_any_psychedelic_approval_2026

2. When will the FDA approve Compass Pathways' COMP360 Psilocybin?

Kalshi · Confidence: high

Matched (medium)pm_kalshi_ddr5_ye2027_above_95 · access=api

Market https://kalshi.com/markets/kxfdaapprovaldatecmps

Why it matters This market is directly tied to the potential FDA approval of COMP360, a lead candidate from Compass Pathways (CMPS), a core theme constituent. An earlier approval would be a significant positive catalyst for CMPS and would set a crucial precedent for other psychedelic drug developers within the theme, validating the regulatory pathway.

Series key pm_fda_cmps_comp360_approval_date

3. Will the FDA approve MDMA for PTSD?

Kalshi · Confidence: high

Matched (medium)pm_kalshi_ddr5_ye2027_above_95 · access=api

Market https://kalshi.com/markets/kxfdaapprove

Why it matters This market directly addresses the potential FDA approval of MDMA for PTSD, which would be a major regulatory breakthrough for a key psychedelic compound. This would significantly benefit companies like PharmAla Biotech (MDMA.CN) and other constituents involved in MDMA development or supply, and further validate the therapeutic potential of psychedelics.

Series key pm_fda_mdma_ptsd_approval

Theme Plain English
This investment theme targets biotechnology companies developing clinical-stage psychedelic compounds and next-generation neuroplastogens for neuropsychiatric disorders, including treatment-resistant depression, PTSD, and generalized anxiety. It encompasses drug developers advancing late-stage pivotal trials toward FDA approvals, alongside specialized picks-and-shovels suppliers providing GMP-grade active pharmaceutical ingredients and therapeutic delivery infrastructure essential for scaling commercial psychedelic-assisted medicine.
Key Metrics3 rows
MetricCadenceWhat It SignalsUpdate Source
Overall Healthcare Market Size and Growth (HLTHSCEXPHCSA)MonthlyGrowth in overall healthcare spending suggests a larger addressable market and increased investment capacity for novel therapies like psychedelics, signaling a bullish trend for the theme.LLM_Approved
Number of Active Psychedelic Clinical StudiesWeeklyAn increasing number of active studies signals robust R&D and a growing pipeline, indicating strong innovation and future potential for drug approvals, supporting a bullish outlook.LLM_Approved
Psychedelic Therapy Market Size ProjectionsAnnually (or as new reports are released)Upward revisions in market size projections indicate increasing confidence in the commercial viability and adoption of psychedelic therapies, signaling a strong bullish trend for the theme.LLM_Approved
Upcoming Catalysts5 rows
CatalystEstimated TimingEstimated Date StartEstimated Date EndWhy It MattersTicker Or Theme SpecificSource TypesContributing TickersMention CountBase ScoreSource WeightSpecificity WeightMacro BridgeMacro Bridge MultiplierTheme ScoreDate AggregatedManual OverrideBridge Mention CountTheme Base ScoreTheme Importance ScoreSource TypeCatalyst Source
Topline Phase 3 data readout for Helus Pharma's HLP003 (deuterated psilocin-related compound) for major depressive disorder. This is a key milestone for a next-generation serotonergic psychedelic.Q4 20262026-10-012026-12-31Positive Phase 3 results for HLP003 would provide crucial validation for next-generation psychedelic compounds, demonstrating their potential in MDD and adding another strong contender to the pipeline of potential FDA-approved therapies, diversifying the theme's drug class exposure.Themetheme_composerHELP, CMPS, DFTX, GHRS, PBM, MDMA.CN, FLHLF, OPTH, NUMIF90.00021.181.0Regulatory/Policy1.350.03712026-10-19False41.6018255.1643theme_composerTheme composer
Potential FDA approval of COMP360 (psilocybin) for treatment-resistant depression. This would mark the first FDA approval of a psychedelic-derived therapy, setting a precedent for the entire industry.Late 2026 - Early 20272026-10-012027-03-31A first FDA approval would be a landmark event, validating the therapeutic potential of psychedelics, potentially opening doors for broader insurance coverage, and significantly de-risking the regulatory pathway for other compounds in the theme.Themetheme_composerCMPS, DFTX, HELP, GHRS, PBM, MDMA.CN, FLHLF, OPTH, NUMIF90.00021.180.92Regulatory/Policy1.350.03412026-10-19False41.6018234.7512theme_composerTheme composer
Topline Phase 3 data readout for Definium Therapeutics' DT120 (LSD-derived therapy) in psychiatric programs. Positive results would further validate LSD-derived compounds and advance DFTX towards potential regulatory submission.Q4 2026 - Q1 20272026-10-012027-03-31Successful Phase 3 data for DT120 would reinforce the efficacy and safety profile of psychedelic-derived treatments, particularly LSD-based therapies, and strengthen the overall investment thesis for the theme by demonstrating a clear path to market for another leading candidate.Themetheme_composerDFTX, CMPS, HELP, GHRS, PBM, MDMA.CN, FLHLF, OPTH, NUMIF90.00021.180.92Regulatory/Policy1.350.03412026-10-19False41.6018234.7512theme_composerTheme composer
Progression of GH Research's inhaled GH001 (mebufotenin/5-MeO-DMT) towards a global Phase 3 program following positive Phase 2b data and U.S. clinical investigation clearance. This will solidify its position as a leading rapid-acting psychedelic.Late 2026 - Early 20272026-10-012027-03-31Advancement into global Phase 3 for GH001 would highlight the potential of rapid-acting psychedelics and 5-MeO-DMT, expanding the therapeutic modalities within the theme beyond psilocybin and LSD, and offering a differentiated approach to treatment-resistant depression.Themetheme_composerGHRS, CMPS, DFTX, HELP, PBM, MDMA.CN, FLHLF, OPTH, NUMIF90.00021.180.921.00.02192026-10-19False11.6018173.8898theme_composerTheme composer
Continued expansion of manufacturing and supply agreements by 'picks-and-shovels' companies like Optimi Health and PharmAla Biotech, driven by increasing demand for pharmaceutical-grade psychedelics for clinical trials and therapeutic use.Ongoing through 2026-20272026-10-192027-12-31Growth in manufacturing and supply is crucial infrastructure for the entire theme. It indicates increasing clinical activity and prepares the market for commercialization, directly benefiting companies providing these essential services and indirectly supporting all drug developers.Themetheme_composerOPTH, MDMA.CN, FLHLF, PBM, NUMIF50.01.180.85Regulatory/Policy1.350.00032026-10-19False40.8108.3263theme_composerTheme composer
NotesTable

Market Commentary

DateTypeCommentDetailSentimentTickers
2026-10-19Theme UpdateThe Biotech '26: Psychedelic Drugs theme shows continued strong momentum, driven by FDA fast-tracking and companies like Compass Pathways nearing NDA submission. Significant market growth is projected, attracting Big Pharma interest. The theme also emphasizes the growing focus on non-hallucinogenic neuroplastogens for broader acceptance, alongside 'picks-and-shovels' and treatment infrastructure plays, despite persistent regulatory and logistical hurdles.

Market Commentary

PositiveCMPS, DFTX, ENVB, OPTH

Loading correlation…

Constituents

  • CMNDT3
    · no notes yet
  • CMPST3
    · no notes yet
  • DFTXT3
    · no notes yet
  • ENVBT3
    · no notes yet
  • FLHLFT3
    · no notes yet
  • GHRST3
    · no notes yet
  • HELPT3
    · no notes yet
  • IBO.VT3
    · no notes yet
  • MDMA.CNT3
    · no notes yet
  • NUMIFT3
    · no notes yet
  • OPTHT3
    · no notes yet
  • PBMT3
    · no notes yet